デフォルト表紙
市場調査レポート
商品コード
1492319

関節リウマチ治療市場:世界の産業分析、規模、シェア、成長、動向、予測、2024-2033年

Rheumatoid Arthritis Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033


出版日
ページ情報
英文 295 Pages
納期
2~5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.30円
関節リウマチ治療市場:世界の産業分析、規模、シェア、成長、動向、予測、2024-2033年
出版日: 2024年05月28日
発行: Persistence Market Research
ページ情報: 英文 295 Pages
納期: 2~5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社は、世界の関節リウマチ(RA)治療市場を詳細に分析し、市場ダイナミクス、成長促進要因・課題、新たな動向を明らかにしています。本レポートは、2024年から2033年までの市場情勢をナビゲートするための包括的なデータと洞察を提供し、利害関係者にとって貴重なリソースとなります。

世界の関節リウマチ治療市場は、2024年から2033年にかけて大きく成長し、この間のCAGRは5.8%と予測されます。同市場は、2024年の475億米ドルから2033年末には791億米ドルに増加すると推定されます。

主な洞察

  • 推定市場価値(2024年):475億米ドル
  • 予測市場価格(2033年):791億米ドル
  • 世界市場成長率(CAGR 2024年~2033年):5.8%

関節リウマチ治療市場:調査範囲

関節リウマチは関節に影響を及ぼす慢性炎症性疾患で、痛みを伴う腫れや関節の変形を引き起こす可能性があります。関節リウマチの有病率の増加、認知度の向上、治療法の進歩が市場を牽引しています。生物学的製剤、疾患修飾性抗リウマチ薬(DMARDs)、新世代の標的療法は、RAの管理において極めて重要です。本レポートでは、2024年から2033年までのRA管理における動向、規制の影響、進歩に焦点を当てながら、これらの治療が果たす重要な役割について詳述します。

市場成長の促進要因:

RA治療市場の成長を促す要因はいくつかあります。関節リウマチの世界の有病率の増加は主要な促進要因であり、RAに罹患しやすい老年人口の増加も同様です。生物学的製剤やバイオシミラー製剤の進歩は、有効性と安全性のプロファイルを改善し、RA管理を一変させました。さらに、ヘルスケア支出の増加、診断技術の向上、RAの早期診断と治療に対する意識の高まりも市場拡大に寄与しています。

市場抑制要因:

前向きな成長見通しにもかかわらず、RA治療市場は課題に直面しています。生物学的製剤は高価であるため、特に発展途上地域では患者へのアクセスが制限される可能性があります。また、副作用の可能性や新しい治療法の長期的な安全性プロファイルも、患者のコンプライアンスに影響を与える懸念材料です。さらに、生物学的製剤やバイオシミラーの規制状況が複雑なため、市場参入が妨げられ、新薬の承認プロセスが遅れる可能性があります。

市場機会:

RA治療市場には、成長とイノベーションの機会がいくつかあります。バイオシミラーの開発は、生物学的製剤に代わる費用対効果の高い選択肢を提供し、治療へのアクセシビリティを高める。個別化医療や、個々の患者プロファイルに合わせた精密治療の進歩は、治療成績を向上させる可能性を秘め、普及しつつあります。RAの有病率が上昇し、ヘルスケアインフラが整備されつつある発展は、大きな成長機会となります。さらに、新規治療標的や併用療法に関する継続的な調査により、より効果的なRA管理が期待されます。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • 市場イノベーション/開発動向

第4章 重要成功要因

  • 治療採用分析
  • 患者の治療体制
  • 主な規制
  • PESTEL分析
  • 主要プレーヤーによる主要なプロモーション戦略

第5章 市場背景

  • マクロ経済要因
  • 予測要因- 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 療法別
    • 流通チャネル別
    • 国別
  • 2024年の市場シナリオ

第7章 世界の関節リウマチ治療市場の需要(金額、規模)分析

  • 過去の市場分析(金額)、2019~2023年
  • 現在および将来の市場予測(金額)、2024~2033年
    • 前年比成長動向分析
    • 絶対的収益機会分析

第8章 世界の関節リウマチ治療市場分析:療法別

  • イントロダクション/主な調査結果
  • 過去の市場規模(金額)の分析、2019~2023年
  • 現在および将来の市場規模(金額)の分析と予測、2024~2033年
    • 対症療法
    • 中等度コルチコステロイド療法
    • 幹細胞療法
    • 疾患修飾抗リウマチ薬(DMARD)
      • 従来のDMARD
      • 生物学的DMARD
  • 療法別市場の魅力分析

第9章 世界の関節リウマチ治療市場分析:流通チャネル別

  • イントロダクション/主な調査結果
  • 過去の市場規模(金額)の分析、2019~2023年
  • 現在および将来の市場規模(金額)の分析と予測、2024~2033年
    • 病院薬局
    • 小売薬局
    • ドラッグストア
  • 流通チャネル別市場の魅力分析

第10章 世界の関節リウマチ治療市場分析:地域別

  • イントロダクション
  • 過去の市場規模(金額)の分析、2019~2023年
  • 現在および将来の市場規模(金額)の分析と予測、2024~2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東およびアフリカ(中東・アフリカ)
  • 地域別市場の魅力分析

第11章 北米の関節リウマチ治療市場分析

第12章 ラテンアメリカの関節リウマチ治療市場分析

第13章 欧州の関節リウマチ治療市場分析

第14章 東アジアの関節リウマチ治療市場分析

第15章 南アジアの関節リウマチ治療市場分析

第16章 オセアニアの関節リウマチ治療市場

第17章 中東・アフリカの関節リウマチ治療市場分析

第18章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第19章 競合分析

  • 競合ダッシュボード
  • 競合の詳細
    • Sanofi SA
    • Pfizer Inc.
    • Johnson &Johnson
    • AbbVie Inc.
    • Eli Lilly &Company
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffman-La Roche AG
    • Cipla, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Sobi Inc.
    • Novartis AG(Sandoz)
    • UCB SA.

第20章 使用される前提条件と頭字語

第21章 調査手法

目次
Product Code: PMRREP22555

Persistence Market Research provides an in-depth analysis of the global Rheumatoid Arthritis (RA) Treatment Market, highlighting market dynamics, growth drivers, challenges, and emerging trends. This report is a valuable resource for stakeholders, offering comprehensive data and insights for navigating the market landscape from 2024 to 2033.

The global rheumatoid arthritis treatment market is projected to grow significantly between 2024 and 2033, with an expected CAGR of 5.8% during this period. The market is estimated to increase from a value of USD 47.5 billion in 2024 to USD 79.1 billion by the end of 2033.

Key Insights:

  • Estimated Market Value (2024): USD 47.5 Billion
  • Projected Market Value (2033): USD 79.1 Billion
  • Global Market Growth Rate (CAGR 2024 to 2033): 5.8%

Rheumatoid Arthritis Treatment Market - Report Scope:

Rheumatoid arthritis is a chronic inflammatory disorder affecting joints, leading to painful swelling and potential joint deformity. The growing prevalence of RA, coupled with increasing awareness and advancements in treatment options, drives the market. Biologic drugs, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), and new-generation targeted therapies are pivotal in managing RA. The report details the significant role of these treatments, highlighting trends, regulatory impacts, and advancements in RA management from 2024 to 2033.

Market Growth Drivers:

Several factors drive the growth of the RA treatment market. The increasing prevalence of rheumatoid arthritis globally is a primary driver, as is the rising geriatric population, which is more susceptible to RA. Advancements in biologic and biosimilar drugs have transformed RA management, offering improved efficacy and safety profiles. Additionally, increased healthcare spending, improved diagnostic techniques, and growing awareness about early RA diagnosis and treatment contribute to market expansion.

Market Restraints:

Despite its positive growth outlook, the RA treatment market faces challenges. The high cost of biologic therapies can limit accessibility for patients, especially in developing regions. Potential side effects and the long-term safety profile of new treatments are also concerns that can affect patient compliance. Moreover, the complex regulatory landscape for biologics and biosimilars can hinder market entry and slow down the approval process for new drugs.

Market Opportunities:

The RA treatment market offers several opportunities for growth and innovation. The development of biosimilars provides a cost-effective alternative to biologics, increasing treatment accessibility. Personalized medicine and advancements in precision therapies tailored to individual patient profiles are gaining traction, potentially improving treatment outcomes. Expanding markets in developing regions, where RA prevalence is rising and healthcare infrastructure is improving, present significant growth opportunities. Additionally, continued research into novel therapeutic targets and combination therapies holds promise for more effective RA management.

Competitive Landscape and Business Strategies:

Leading companies in the RA treatment market include AbbVie Inc., Amgen Inc., and Pfizer Inc. These companies focus on research and development to introduce innovative therapies and improve existing treatments. Strategic collaborations, mergers, and acquisitions are common strategies to enhance market presence and expand product portfolios. For instance, AbbVie's Humira and Pfizer's Xeljanz are well-known RA treatments that contribute significantly to their respective market shares.

Companies are also investing in patient support programs and educational initiatives to improve treatment adherence and outcomes. Expanding distribution networks and leveraging digital platforms for patient engagement are additional strategies employed by key players to sustain growth and maintain a competitive edge.

Key Companies Profiled:

  • AbbVie Inc.
  • Amgen Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Roche Holding AG
  • UCB S.A.
  • Eli Lilly and Company
  • Sanofi S.A.

Rheumatoid Arthritis Treatment Market Segmentation:

Therapy:

  • Symptomatic Treatment
  • Intermediate Corticosteroid Therapies
  • Stem Cell Therapy
  • Disease Modifying Anti-rheumatic Drug (DMARD)

Conventional DMARDs

Biologic DMARDs

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Drug Stores

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Market Innovation / Development Trends

4. Key Success Factors

  • 4.1. Therapy Adoption Analysis
  • 4.2. Patient Treatment Regime
  • 4.3. Key Regulations
  • 4.4. PESTEL Analysis
  • 4.5. Key Promotional Strategies, By Key Players

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Increase in R&D Spending
    • 5.2.2. Growing Lifestyle Disease Prevalence
    • 5.2.3. Cost of Therapy
    • 5.2.4. Strategic Collaborations
    • 5.2.5. Changes in Regulatory Policies
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Therapy
    • 6.1.2. By Distribution Channel
    • 6.1.3. By Country
  • 6.2. 2024 Market Scenario

7. Global Rheumatoid Arthritis Treatment Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Therapy

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis By Therapy, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Therapy, 2024-2033
    • 8.3.1. Symptomatic Treatment
    • 8.3.2. Intermediate Corticosteroid Therapies
    • 8.3.3. Stem Cell Therapy
    • 8.3.4. Disease Modifying Anti-rheumatic Drug (DMARD)
      • 8.3.4.1. Conventional DMARDs
      • 8.3.4.2. Biologic DMARDs
  • 8.4. Market Attractiveness Analysis By Therapy

9. Global Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Drug Stores
  • 9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
  • 10.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2024-2033
    • 10.3.1. North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. East Asia
    • 10.3.5. South Asia
    • 10.3.6. Oceania
    • 10.3.7. Middle East and Africa (MEA)
  • 10.4. Market Attractiveness Analysis By Region

11. North America Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 11.3.1. By Country
      • 11.3.1.1. U.S.
      • 11.3.1.2. Canada
    • 11.3.2. By Therapy
    • 11.3.3. By Distribution Channel
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Country
    • 11.4.2. By Therapy
    • 11.4.3. By Distribution Channel
  • 11.5. Market Trends
  • 11.6. Drivers and Restraints - Impact Analysis
  • 11.7. Key Players - Intensity Mapping
  • 11.8. Country Level Analysis & Forecast
    • 11.8.1. U.S. Rheumatoid Arthritis Treatment Market Analysis
      • 11.8.1.1. Introduction
      • 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.1.2.1. By Therapy
        • 11.8.1.2.2. By Distribution Channel
    • 11.8.2. Canada Rheumatoid Arthritis Treatment Market Analysis
      • 11.8.2.1. Introduction
      • 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.2.2.1. By Therapy
        • 11.8.2.2.2. By Distribution Channel

12. Latin America Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 12.3.1. By Country
      • 12.3.1.1. Mexico
      • 12.3.1.2. Brazil
      • 12.3.1.3. Argentina
      • 12.3.1.4. Rest of Latin America
    • 12.3.2. By Therapy
    • 12.3.3. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Therapy
    • 12.4.3. By Distribution Channel
  • 12.5. Market Trends
  • 12.6. Drivers and Restraints - Impact Analysis
  • 12.7. Key Players - Intensity Mapping
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. Mexico Rheumatoid Arthritis Treatment Market Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Therapy
        • 12.8.1.2.2. By Distribution Channel
    • 12.8.2. Brazil Rheumatoid Arthritis Treatment Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Therapy
        • 12.8.2.2.2. By Distribution Channel
    • 12.8.3. Argentina Rheumatoid Arthritis Treatment Market Analysis
      • 12.8.3.1. Introduction
      • 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.3.2.1. By Therapy
        • 12.8.3.2.2. By Distribution Channel

13. Europe Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. Germany
      • 13.3.1.2. Italy
      • 13.3.1.3. France
      • 13.3.1.4. U.K.
      • 13.3.1.5. Spain
      • 13.3.1.6. BENELUX
      • 13.3.1.7. Russia
      • 13.3.1.8. Rest of Europe
    • 13.3.2. By Therapy
    • 13.3.3. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Therapy
    • 13.4.3. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Key Players - Intensity Mapping
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Germany Rheumatoid Arthritis Treatment Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Therapy
        • 13.8.1.2.2. By Distribution Channel
    • 13.8.2. Italy Rheumatoid Arthritis Treatment Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Therapy
        • 13.8.2.2.2. By Distribution Channel
    • 13.8.3. France Rheumatoid Arthritis Treatment Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Therapy
        • 13.8.3.2.2. By Distribution Channel
    • 13.8.4. U.K. Rheumatoid Arthritis Treatment Market Analysis
      • 13.8.4.1. Introduction
      • 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.4.2.1. By Therapy
        • 13.8.4.2.2. By Distribution Channel
    • 13.8.5. Spain Rheumatoid Arthritis Treatment Market Analysis
      • 13.8.5.1. Introduction
      • 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.5.2.1. By Therapy
        • 13.8.5.2.2. By Distribution Channel
    • 13.8.6. BENELUX Rheumatoid Arthritis Treatment Market Analysis
      • 13.8.6.1. Introduction
      • 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.6.2.1. By Therapy
        • 13.8.6.2.2. By Distribution Channel
    • 13.8.7. Russia Rheumatoid Arthritis Treatment Market Analysis
      • 13.8.7.1. Introduction
      • 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.7.2.1. By Therapy
        • 13.8.7.2.2. By Distribution Channel

14. East Asia Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. China
      • 14.3.1.2. Japan
      • 14.3.1.3. South Korea
    • 14.3.2. By Therapy
    • 14.3.3. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Therapy
    • 14.4.3. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Key Players - Intensity Mapping
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. China Rheumatoid Arthritis Treatment Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Therapy
        • 14.8.1.2.2. By Distribution Channel
    • 14.8.2. Japan Rheumatoid Arthritis Treatment Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Therapy
        • 14.8.2.2.2. By Distribution Channel
    • 14.8.3. South Korea Rheumatoid Arthritis Treatment Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Therapy
        • 14.8.3.2.2. By Distribution Channel

15. South Asia Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Indonesia
      • 15.3.1.3. Malaysia
      • 15.3.1.4. Thailand
      • 15.3.1.5. Rest of South Asia
    • 15.3.2. By Therapy
    • 15.3.3. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Therapy
    • 15.4.3. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Key Players - Intensity Mapping
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. India Rheumatoid Arthritis Treatment Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Therapy
        • 15.8.1.2.2. By Distribution Channel
    • 15.8.2. Indonesia Rheumatoid Arthritis Treatment Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Therapy
        • 15.8.2.2.2. By Distribution Channel
    • 15.8.3. Malaysia Rheumatoid Arthritis Treatment Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Therapy
        • 15.8.3.2.2. By Distribution Channel
    • 15.8.4. Thailand Rheumatoid Arthritis Treatment Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Therapy
        • 15.8.4.2.2. By Distribution Channel

16. Oceania Rheumatoid Arthritis Treatment Market 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. Australia
      • 16.3.1.2. New Zealand
    • 16.3.2. By Therapy
    • 16.3.3. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Therapy
    • 16.4.3. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Key Players - Intensity Mapping
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. Australia Rheumatoid Arthritis Treatment Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Therapy
        • 16.8.1.2.2. By Distribution Channel
    • 16.8.2. New Zealand Rheumatoid Arthritis Treatment Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Therapy
        • 16.8.2.2.2. By Distribution Channel

17. Middle East and Africa (MEA) Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. GCC Countries
      • 17.3.1.2. Turkey
      • 17.3.1.3. North Africa
      • 17.3.1.4. South Africa
      • 17.3.1.5. Rest of Middle East and Africa
    • 17.3.2. By Therapy
    • 17.3.3. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Therapy
    • 17.4.3. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Key Players - Intensity Mapping
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. GCC Countries Rheumatoid Arthritis Treatment Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Therapy
        • 17.8.1.2.2. By Distribution Channel
    • 17.8.2. Turkey Rheumatoid Arthritis Treatment Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Therapy
        • 17.8.2.2.2. By Distribution Channel
    • 17.8.3. South Africa Rheumatoid Arthritis Treatment Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Therapy
        • 17.8.3.2.2. By Distribution Channel
    • 17.8.4. North Africa Rheumatoid Arthritis Treatment Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Therapy
        • 17.8.4.2.2. By Distribution Channel

18. Market Structure Analysis

  • 18.1. Market Analysis by Tier of Companies
  • 18.2. Market Share Analysis of Top Players
  • 18.3. Market Presence Analysis

19. Competition Analysis

  • 19.1. Competition Dashboard
  • 19.2. Competition Deep Dive
    • 19.2.1. Sanofi S.A.
      • 19.2.1.1. Overview
      • 19.2.1.2. Product Portfolio
      • 19.2.1.3. Sales Footprint
      • 19.2.1.4. Key Financials
      • 19.2.1.5. SWOT Analysis
      • 19.2.1.6. Strategy Overview
        • 19.2.1.6.1. Marketing Strategy
        • 19.2.1.6.2. Channel Strategy
    • 19.2.2. Pfizer Inc.
      • 19.2.2.1. Overview
      • 19.2.2.2. Product Portfolio
      • 19.2.2.3. Sales Footprint
      • 19.2.2.4. Key Financials
      • 19.2.2.5. SWOT Analysis
      • 19.2.2.6. Strategy Overview
        • 19.2.2.6.1. Marketing Strategy
        • 19.2.2.6.2. Channel Strategy
    • 19.2.3. Johnson & Johnson
      • 19.2.3.1. Overview
      • 19.2.3.2. Product Portfolio
      • 19.2.3.3. Sales Footprint
      • 19.2.3.4. Key Financials
      • 19.2.3.5. SWOT Analysis
      • 19.2.3.6. Strategy Overview
        • 19.2.3.6.1. Marketing Strategy
        • 19.2.3.6.2. Channel Strategy
    • 19.2.4. AbbVie Inc.
      • 19.2.4.1. Overview
      • 19.2.4.2. Product Portfolio
      • 19.2.4.3. Sales Footprint
      • 19.2.4.4. Key Financials
      • 19.2.4.5. SWOT Analysis
      • 19.2.4.6. Strategy Overview
        • 19.2.4.6.1. Marketing Strategy
        • 19.2.4.6.2. Channel Strategy
    • 19.2.5. Eli Lilly & Company
      • 19.2.5.1. Overview
      • 19.2.5.2. Product Portfolio
      • 19.2.5.3. Sales Footprint
      • 19.2.5.4. Key Financials
      • 19.2.5.5. SWOT Analysis
      • 19.2.5.6. Strategy Overview
        • 19.2.5.6.1. Marketing Strategy
        • 19.2.5.6.2. Channel Strategy
    • 19.2.6. Amgen Inc.
      • 19.2.6.1. Overview
      • 19.2.6.2. Product Portfolio
      • 19.2.6.3. Sales Footprint
      • 19.2.6.4. Key Financials
      • 19.2.6.5. SWOT Analysis
      • 19.2.6.6. Strategy Overview
        • 19.2.6.6.1. Marketing Strategy
        • 19.2.6.6.2. Channel Strategy
    • 19.2.7. Bristol-Myers Squibb Company
      • 19.2.7.1. Overview
      • 19.2.7.2. Product Portfolio
      • 19.2.7.3. Sales Footprint
      • 19.2.7.4. Key Financials
      • 19.2.7.5. SWOT Analysis
      • 19.2.7.6. Strategy Overview
        • 19.2.7.6.1. Marketing Strategy
        • 19.2.7.6.2. Channel Strategy
    • 19.2.8. F. Hoffman-La Roche AG
      • 19.2.8.1. Overview
      • 19.2.8.2. Product Portfolio
      • 19.2.8.3. Sales Footprint
      • 19.2.8.4. Key Financials
      • 19.2.8.5. SWOT Analysis
      • 19.2.8.6. Strategy Overview
        • 19.2.8.6.1. Marketing Strategy
        • 19.2.8.6.2. Channel Strategy
    • 19.2.9. Cipla, Inc.
      • 19.2.9.1. Overview
      • 19.2.9.2. Product Portfolio
      • 19.2.9.3. Sales Footprint
      • 19.2.9.4. Key Financials
      • 19.2.9.5. SWOT Analysis
      • 19.2.9.6. Strategy Overview
        • 19.2.9.6.1. Marketing Strategy
        • 19.2.9.6.2. Channel Strategy
    • 19.2.10. Sun Pharmaceutical Industries Ltd.
      • 19.2.10.1. Overview
      • 19.2.10.2. Product Portfolio
      • 19.2.10.3. Sales Footprint
      • 19.2.10.4. Key Financials
      • 19.2.10.5. SWOT Analysis
      • 19.2.10.6. Strategy Overview
        • 19.2.10.6.1. Marketing Strategy
        • 19.2.10.6.2. Channel Strategy
    • 19.2.11. Sobi Inc.
      • 19.2.11.1. Overview
      • 19.2.11.2. Product Portfolio
      • 19.2.11.3. Sales Footprint
      • 19.2.11.4. Key Financials
      • 19.2.11.5. SWOT Analysis
      • 19.2.11.6. Strategy Overview
        • 19.2.11.6.1. Marketing Strategy
        • 19.2.11.6.2. Channel Strategy
    • 19.2.12. Novartis AG ( Sandoz)
      • 19.2.12.1. Overview
      • 19.2.12.2. Product Portfolio
      • 19.2.12.3. Sales Footprint
      • 19.2.12.4. Key Financials
      • 19.2.12.5. SWOT Analysis
      • 19.2.12.6. Strategy Overview
        • 19.2.12.6.1. Marketing Strategy
        • 19.2.12.6.2. Channel Strategy
    • 19.2.13. UCB S.A..
      • 19.2.13.1. Overview
      • 19.2.13.2. Product Portfolio
      • 19.2.13.3. Sales Footprint
      • 19.2.13.4. Key Financials
      • 19.2.13.5. SWOT Analysis
      • 19.2.13.6. Strategy Overview
        • 19.2.13.6.1. Marketing Strategy
        • 19.2.13.6.2. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology